IL6 and neoplasm: A standard dose of EPA inhibits tumour growth-induced lipolysis and muscle protein degradation, possibly by suppressing the cytokine IL-6 and reducing a tumour-specific product that is a proteolysis-inducing factor (PIF) EPA improved prolonged survival, enhanced weight maintenance, ameliorated food intake and reduced protein degradation without effecting protein synthesis.